Amarin (AMRN) Vascepa Pricing Leak?
Tweet Send to a Friend
Get Alerts AMRN Hot Sheet
Down)
Trade AMRN Now!
Amarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although the website has since been updated and the prices removed.
Investors were taken off-guard given the fact that Amarin hasn't even disclosed what strategy it will use to launch the FDA-approved triglyceride lowering drug. The company will either go it alone, partner with a large pharma or get acquired by a large pharma.
Recently the company delayed hiring Vascepa sales reps until early December, which has some speculating a takeover is more likely. However, an FDA decision on NCE status for Vascepa is considered to be a major sticking point for potential suitors. After months of delays on NCE status, a decision could finally come before the next Orange Book update date of December 14.
The company did not respond to a question from StreetInsider.com about the
GoodRx pricing.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although the website has since been updated and the prices removed.
Investors were taken off-guard given the fact that Amarin hasn't even disclosed what strategy it will use to launch the FDA-approved triglyceride lowering drug. The company will either go it alone, partner with a large pharma or get acquired by a large pharma.
Recently the company delayed hiring Vascepa sales reps until early December, which has some speculating a takeover is more likely. However, an FDA decision on NCE status for Vascepa is considered to be a major sticking point for potential suitors. After months of delays on NCE status, a decision could finally come before the next Orange Book update date of December 14.
The company did not respond to a question from StreetInsider.com about the
GoodRx pricing.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Yahoo!'s (YHOO) Mayer: We Won't Screw Up Tumblr!
- Can AMD (AMD) Shake Off the Goldman Downgrade?
Create E-mail Alert Related Categories
FDA, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
